Earlier trials also showed improvements in LVOT gradient and NYHA class, though some did not reach statistical significance [ 60 , 61 , 62 ].
← all excerpts
Cardiac Myosin Inhibitors in the Treatment of Hypertrophic Cardiomyopathy: Clinical Trials and Future Challenges.
1
—
—